Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
49.92 USD | +1.30% | +1.34% | +0.52% |
05:28pm | CAC40: symbolic losses, 'volat' rises at W-Street | CF |
04:16pm | Trending : Fulcrum Therapeutics, Sanofi in Losmapimod Licensing Deal | DJ |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The opinion of analysts covering the stock has improved over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.52% | 127B | - | ||
+29.38% | 684B | C+ | ||
+30.34% | 568B | B | ||
-3.80% | 361B | C+ | ||
+17.64% | 329B | B- | ||
+4.23% | 284B | C+ | ||
+16.21% | 240B | B+ | ||
+9.66% | 208B | B- | ||
-6.83% | 200B | A+ | ||
+7.45% | 166B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SAN Stock
- SNY Stock
- Ratings Sanofi